iNova’s trusted brands improve people’s health and well-being everyday
Vision
iNova’s trusted brands improve people’s health and well-being everyday
Purpose
Recognised by Healthcare professionals, their patients and consumers as a trusted expert and partner for their health and wellness needs
A dynamic and motivated team engaged to collectively achieve our full potential
Nimble, hungry and innovative in everything we do
Respected for delivering trusted, market leading, healthcare products and solutions through a high performing operating platform
Values
Act ethically
Do the right thing …
everyday and in everything we do
Customers: always front of mind
Really listen to and consider our HCP partners, their patients and consumers in everything we do
Own it
Be involved:
see it, say it, do it
Do our best
Be the best at what we do:
expert in our business, brands
and customers
Embrace the pace
Decide fast, win fast,
fail fast, learn fast, fix fast
Shift our thinking
Be bold and brave:
what could we do …
what will it take
Demazin is a well-known, pharmacy only brand, that has been a staple of Australian medicine cabinets for over 50 years. Despite strong success for many decades, ownership changes in more recent years caused Demazin to suffer significant sales decline due to a lack of focus and support.
When iNova acquired Demazin from Bayer in 2019, we did so with the intention to revitalise the brand and restore it to its former glory. In just over 12 months the Australian team developed a revised brand strategy, created four new Demazin products to fill gaps in the range, developed new-look packaging to refresh the brand and launched it back into market with a fresh and fun television advertising campaign featuring the old favourite ‘D-D-Demazin’ mnemonic.
With iNova’s strong investment, distribution reach and strong pharmacy relationships, we are confident Demazin will grow to again be the ‘go-to’ brand for the whole family.
Demazin is exactly the type of brand that iNova looks to own or distribute – a proven and effective product with an established reputation among healthcare professionals and consumers, that, with a bit of investment and focus, has the potential to grow.
Our door is always open to prospective vendors and business partners here at iNova Pharmaceuticals!
Viral Guard
Application Dates:12 weeks
Location:Sydney NSW, Australia
The Challenge
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch innovative products or ingredients that have an Anti-Viral Mechanism of action which can help prevent cold & flu symptoms and shorten the duration of cold symptoms by blocking viruses if taken preventatively or at the first signs of a cold. Your product can be a medical device or herbal natural product with a nasal or throat delivery system (e.g. Nasal spray, throat spray, lozenge).
Ideal Solution
your idea is innovative, can be commercialised and is backed by sufficient clinical and/or scientific evidence to support claims relating to Cold prevention and Anti-Viral mechanism of action.
you already or have the potential to manufacture your product(s) in a pharmaceutical GMP manufacturing facility
you have or the potential to generate stability data to support a minimum 24 months shelf life
the materials and ingredients that you are using can be used for therapeutic goods within Australia and there is sustainability in supply
if your product is a device, you can provide a valid ISO certificate for the legal manufacturer(s) of your product(s), EC Certificates and confirm if the product(s) is certified to the EU MDD or the EU MDR
environmental footprint and sustainability has been considered
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and manufacturers to pitch ideas for COVID-19 related consumer healthcare solutions. We are looking for consumer healthcare related solutions and products that help our consumer in a COVID-19 context.
Ideal Solution
How can iNova better meet the needs of consumers in a COVID-19 world? As a wild card category, you are not limited by category or format. Rather we are looking for novel solutions that help consumers navigate the ‘new normal’ in a COVID-19 and post-COVID-19 world. The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations/formats are a strong fit for one or more of the iNova portfolio of brands
your products are available to sell in Australia/New Zealand, and/or South Africa, and/or Asia
you already produce products/prototypes containing scientifically proven or clinically proven ingredients on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
We are inviting packaging developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to assist us in the journey of making our Kynd brand more sustainable.
The Kynd brand incorporates the philosophy of being kind to the planet, being sustainable wherever possible. In its current range of six products – five are in a glass bottle with bamboo lids and the sixth is in a cardboard carton with plastic/foil sachets. We are looking for innovative products or solutions that will allow existing product packaging to be even more sustainable or future products for potential line extensions.
For example, we are using a 100% recycled cardboard box for e-commerce shippers (a box to avoid breakages with the glass products) rather than producing new materials.
We are open to hear about packaging solutions in area such as, or in replacement of jars, bottles, caps, lids, pump bottles, spray bottles, vials, pouches, sachets, etc.
Ideal Solution
How can we better meet the needs of our planet and appeal to customer groups who are wanting to be more sustainable in their purchase decisions? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a cost-effective solution to promoting the brand’s stance on sustainability.
your products are available for use in Australia
you are able to produce or provide a sample of your sustainable solution from your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the solution
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting tissue manufacturers to pitch a vapour release pocket tissue which provides fast relief from a blocked nose and mild headache. The tissues can be used on the go or dropped into a steam bath for inhaling the released vapours. The product must be infused with strong mentholated volatile oils. The packaging should be resealable with wet and dry tissue options.
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea can be readily commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for our key Asia markets – Thailand, Philippines, Malaysia, Singapore and Hong Kong
you already produce products/prototypes containing safe ingredients under your own brand or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch differentproductformat innovation to drive growth for our sore throat brands – DIFFLAM brand in Australia, New Zealand and Asia, or ANDOLEX brand in South Africa. Difflam is the #1 sore throat brand in pharmacy in Australia*. Andolex is South Africa’s leading brand for sore throat and mouth**. We currently have formats in lozenge, spray and gargle formats. We are looking for new, different and innovative formats for our various sore throat formulations. We currently have the following products combinations:-
** IMS Total Private Market Value MAT. December 2018.
Ideal Solution
How can iNova better meet the needs of consumers in delivering different sore throat formats across our various formulations? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations/formats are a strong fit for the Difflam and Andolex brand portfolio
your products are available to sell in Australia/New Zealand, Asia and/or South Africa
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch differentproductformat innovation to drive growth for our hay fever and allergy brands – DEMAZIN brand in Australia, New Zealand, or RUPANASE and Allerguard brands in South Africa. We currently have formats in lozenge, liquid and tablet formats. We are looking for new, different and innovative formats for our various hay fever and allergy brands
Ideal Solution
How can iNova better meet the needs of consumers in delivering different formats across our various hay fever and allergy formulations? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations/formats are a strong fit for the Demazin and/or Rupanase/Allerguard brand portfolios
your products are available to sell in Australia/New Zealand, and/or South Africa
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch a Lingering Cough Lozenge that helps to suppress your nagging cough symptoms & soothe throat irritation, enabling consumers to work, play or sleep better and feel fully recovered. The product should be suitable for adults and children 6 years & above.
This new Lingering Cough Lozenge should contain natural/herbal extracts. It may work as a demulcent by forming a protective coating on the throat, thus shielding it from irritants. These extract(s) have a long history and are used in western or Asian traditional herbal medicines for the symptomatic treatment/management/relief of symptoms of irritated oral and throat conditions and associated dry cough.
For traditional medicines, ingredients in official pharmacopoeias are preferred, i.e. British Herbal Pharmacopoeia, British Herbal Compendium, European Pharmacopoeia, German Pharmacopoeia, Japanese Pharmacopoeia, Ayurvedic Pharmacopoeia etc. Any combinations of traditional ingredients must be substantiated by a particular herbal monograph or textbook, not merely the substantiation of the individual ingredients.
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea can be readily commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for our key regions – Australia/New Zealand, Asia and South Africa
you already produce products/prototypes containing safe ingredients under your own brand or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch differentproductformat innovation to drive growth for our Cough & Cold brands – DURO-TUSS brand in Australia, New Zealand and Asia, or Pholtex brand in South Africa. We currently have formats in lozenge, liquid and tablet formats. We are looking for new, different and innovative formats for our various cough cold brands
Ideal Solution
How can iNova better meet the needs of consumers in delivering different formats across our various cough and cold formulations? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations/formats are a strong fit for the Durotuss and/or Pholtex brand portfolios
your products are available to sell in Australia/New Zealand, Asia and/or South Africa
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch differentproductformat innovation to drive growth for our Cold & Flu brands – DEMAZIN brand in Australia, New Zealand and Asia, or FLUGON brand in South Africa. We currently have formats in lozenge, liquid, hot drink, effervescent and tablet formats. We are looking for new, different and innovative formats for our various iNova cold and flu brands
Ideal Solution
How can iNova better meet the needs of consumers in delivering different formats across our various cough and cold formulations? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations/formats are a strong fit for the Demazin and/or FluGon brand portfolios
your products are available to sell in Australia/New Zealand, Asia and/or South Africa
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch innovative products or ingredients which can help to relieve bronchitis or dry / unproductive coughs. Your product can be a medicine using either allopathic or herbal ingredients or a device.
For traditional medicines, ingredients in official pharmacopoeias are preferred, i.e. British Herbal Pharmacopoeia, British Herbal Compendium, European Pharmacopoeia, German Pharmacopoeia, Japanese Pharmacopoeia, Ayurvedic Pharmacopoeia etc. Any combinations of traditional ingredients must be substantiated by a particular herbal monograph or textbook, not merely the substantiation of the individual ingredients.
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over other dry or bronchitis cough products that are currently on the market/in use by iNova cough & cold brands
you already or have the potential to manufacture your product(s) in a pharmaceutical GMP manufacturing facility
you have sufficient clinical and / or scientific evidence to support claims relating to relief of dry or bronchitis cough
you already or have the potential to generate stability data to support a minimum 24 months shelf life
the materials and ingredients that you are using can be used for therapeutic goods within Australia and there is sustainability in supply
if your product is a device, you can provide a valid ISO certificate for the legal manufacturer(s) of your product(s), EC Certificates and confirm if the product(s) is certified to the EU MDD or the EU MDR
environmental footprint and sustainability has been considered
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting packaging developers, packaging designers and innovators to pitch designs or solutions to iNova for innovative packaging solutions for throat, cough, cold & flu, sinus, allergy consumer healthcare products. We are looking for both innovative packaging formats as well as dosing devices which make using, administering, storing and carrying winter and spring healthcare products easier for our consumers.
Ideal Solution
How can iNova better meet the needs of consumers in delivering their winter and spring healthcare products in a way that makes using them frictionless and easier? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over packaging currently on the market/in use by iNova winter/spring brands
your packaging idea is available to use in our key iNova markets – Australia/New Zealand, Asia and/or South Africa
you already produce packaging/prototypes being submitted for therapeutic products in a GMP manufacturing facility (or have the potential to be)
the cost to develop and product your packaging is commensurate to current packaging used for therapeutic product packaging and your idea is not cost prohibitive relative to current options
the materials you are using can be used for therapeutic goods and there is sustainability in supply.
environmental footprint and sustainability is a key aspect of your solution
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Sustained Release/Long Lasting Formats for Winter Products
Application Dates:12 weeks
Location:Singapore
The Challenge
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch a sustained-release product providing longer lasting relief from upper respiratory tract ailments such as sore throats, dry/chesty coughs, cold & flu. We are looking for a product with minimal dosage frequency and a duration claim (eg, relief for x hours). Ideally, twice or once a day that gives relief for 12 or then 24 hours & allows us to make a claim on the pack & in health professional/consumer communication. The products could be several different formats – solid (lozenges, pastilles, capsule, tablets) or liquid (syrups, suspensions, etc). The sustained release feature of the formulation is based on a special delivery technology or a special ingredient or property of the active or excipient. The same should be established and/or backed by validated biopharmaceutical evidence, including clinical data/studies, in accordance with the EU Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1).
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea can be readily commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for our key Asia markets – Thailand, Philippines, Malaysia, Singapore and Hong Kong
you already produce products/prototypes containing safe ingredients under your own brand or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting face mask manufacturers to pitch a specially designed mask which comes impregnated with natural essential oils, that helps to prevent the spread of infection, clears the nose and aids in breathing for those suffering from a cough & cold. The masks should deliver long lasting continual relief and be infused with volatile oils like eucalyptus, peppermint, thyme using a microencapsulation technology. The mask should be formaldehyde-free, biodegradable and compostable, uses generally skin safe microencapsulated fragrances, does not contain micro-plastics and is not animal tested.
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea can be readily commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for our key Asia markets – Thailand, The Philippines, Malaysia, Singapore and Hong Kong
you already produce products/prototypes containing safe ingredients under your own brand or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Norflex brand in South Africa. Norflex is the number one prescribed muscle relaxant brand in South Africa1. We are looking for innovative topical spray products which treat strain and sprain injuries; muscle, tendon or ligament injuries accompanied by pain, swelling and inflammation.
1. Impact Rx. Script Data – February 2018.
Ideal Solution
How can iNova better meet the needs of consumers in delivering strain and sprain solutions? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for the Norflex brand portfolio
your products are available to sell in South Africa and or other African countries
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our PregOmega and Pregnavit M brands in South Africa. PregOmega is the number 1 prenatal choice* in South Africa. We are looking for innovative products and ingredients that are proven or well known to be safe for use in pregnancy.
* IMS:TPM Data (A11A, A11B, A11E, V6D, V3X / Constructed Class). MAT February 2019.
Ideal Solution
How can iNova better meet the needs of consumers in delivering products for pregnant women? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for the PregOmega and Pregnavit M brand portfolio
your products are available to sell in South Africa
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
your products/ formulations are proven or known to be safe for use by pregnant women
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch innovative products or ingredients which can help to relieve sinusitis. Your product can be allopathic or herbal ingredients or a device such as a nasal irrigation system.
Ideal Solution
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over other sinus relief products that are currently on the market/in use by iNova cough & cold brands
you already or have the potential to manufacture your product(s) in a pharmaceutical GMP manufacturing facility
you have sufficient clinical and/or scientific evidence to support claims relating to relief of sinusitis
you already or have the potential to generate stability data to support a minimum 24 months shelf life
The materials and ingredients that you are using can be used for therapeutic goods within Australia and there is sustainability in supply
If your product is a device, you can provide a valid ISO certificate for the legal manufacturer(s) of your product(s), EC Certificates and confirm if the product(s) is certified to the EU MDD or the EU MDR
environmental footprint and sustainability has been considered
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting food manufacturers or GMP certified manufacturers to pitch a refreshing mouth melt which delivers an instant burst of menthol. The product will be specially developed with ingredients that rapidly dissolve when in contact with saliva, releasing the menthol refreshment in an instant. The product should be in the form of small beads or tablets (approximately 0.5 – 1.5 g) or the like, packaged in a small handy pack with different flavour options.
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea can be readily commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for our key Asia markets – Thailand, Philippines, Malaysia, Singapore and Hong Kong
you already produce products/prototypes containing safe ingredients under your own brand or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting food or GMP certified manufacturers to pitch a pastille which not only delivers a mega-hit of menthol but is also enriched with ingredients such as vitamin B that supports mental performance and provides a refreshing boost. The product should only contain natural flavours and colours with no added sugar.
Ideal Solution
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea can be readily commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for our key Asia markets – Thailand, Philippines, Malaysia, Singapore and Hong Kong
you already produce products/prototypes containing safe ingredients under your own brand or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. Leading applications will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Dermatix brand, Australia’s #1 scar reduction gel*.
Ideal Solution
How can iNova better meet the needs of consumers in delivering wounds and scar solutions? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for the Dermatix brand portfolio
your products are available to sell in Australia and/or New Zealand
your product can be sold over the counter, without a Doctor’s script
you already produce products/prototypes containing evidence-based ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Opportunity?
Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging the Dermatix branding – familiar to Australian and New Zealand consumers. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across ANZ. Should the idea be valid for other iNova regions, there will also be the opportunity to extend the products to Asia and South Africa where iNova have a presence (possibly under a different brand).
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solutions will then be launched in Australia and/or New Zealand, under the mutually agreed partnership model.
Who Should Apply?
If you or your organisation has products, technology or fast R&D solutions which can deliver to stretching our Dermatix brand, then please APPLICATIONS NOW CLOSED.
* Aztec Pharmacy Scan Data (Value), Scar Treatment Gels. MAT 9/6/19
Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.
NOTICE: You are leaving the iNova Pharmaceuticals website and are being directed to a website hosted by CoVentured. While we have a relationship with CoVentured, we do not endorse or guarantee any CoVentured website and we disclaim any liability relating thereto. The CoVentured website will also have different security and privacy policies and practices. By continuing, you acknowledge and agree to the foregoing.
iNova iPitch - Vapourising Delivery System Challenge
Application Dates:
23 Sep, 2019 12AM – 18 Nov, 2019 11PM
The Challenge
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Nyal brand in the Australian market, the #1 Cough Liquid & Nasal Spray Brand*. We are interested in novel and unique delivery systems for natural ingredients, such as menthol, to clear the nose and head for immediate relief. Appealing formats could include inhaler sticks, topical rub sticks, sprays, patches or vapourisers which are suitable for use both at home and on-the-go. The product should also be differentiated from current competitors.
Ideal Solution
How can iNova better meet the needs of consumers in delivering better products? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for the Nyal brand portfolio
your products are available to sell in Australia
you already produce products/prototypes containing evidence-based ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Opportunity?
Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on the strong, well-known Nyal branding – familiar to the Australian consumer. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia. Should the idea be also valid for our other regions, there will also be the opportunity to extend the products to Asia and South Africa where we have a presence (possibly under a different brand).
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solution(s) will then be launched in Australia, under the mutually agreed partnership model.
Who Should Apply?
If you or your organisation has products, technology or fast R&D solutions which can deliver to stretching our Nyal brand, then please APPLICATIONS NOW CLOSED.
Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.
NOTICE: You are leaving the iNova Pharmaceuticals website and are being directed to a website hosted by CoVentured. While we have a relationship with CoVentured, we do not endorse or guarantee any CoVentured website and we disclaim any liability relating thereto. The CoVentured website will also have different security and privacy policies and practices. By continuing, you acknowledge and agree to the foregoing.
Inviting Consumer Health product developers, innovators and/or GMP (Good Manufacturing Practice) certified manufacturers to pitch products or solutions to drive growth for our Difflam brand in Australasia or Andolex brand in South Africa. Difflam is the #1 sore throat brand in pharmacy in Australia*. Andolex is South Africa’s leading brand for sore throat and mouth**. We are looking for innovative products or ingredients which treat sore throats across all life stages from young children to the elderly.
Ideal Solution
How can iNova better meet the needs of consumers in delivering sore throat solutions across different life stages? The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea is innovative, can be commercialised and will deliver a clear consumer benefit over products currently on the market
your products/formulations are a strong fit for the Difflam and Andolex brand portfolio
your products are available to sell in Australia/New Zealand, Asia and/or South Africa
you already produce products/prototypes containing scientifically proven ingredients or clinically proven formula/mode of action on your behalf or on behalf of third parties
you are willing and authorised to negotiate an agreement to cover the development and manufacture of the product
you are willing and authorised to discuss ownership of Intellectual Property (we would prefer full assignment of rights to iNova Pharmaceuticals or at least exclusive license of rights)
your organisation is nimble and able to support fast development and manufacturing
What is the Opportunity?
Leading Innovators will partner with iNova Pharmaceuticals to take their product to the next level, leveraging on our world-famous brands. iNova Pharmaceuticals is also well placed with an established network of distributors and customers across Australia/New Zealand, Asia and/or South Africa.
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solution(s) will then be launched into one or more of our regions, under the mutually agreed partnership model.
Who Should Apply?
If you or your organisation has products, technology or fast R&D solutions for iNova throat brands, then please APPLICATIONS NOW CLOSED.
** IMS Total Private Market Value MAT. December 2018.
Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.
NOTICE: You are leaving the iNova Pharmaceuticals website and are being directed to a website hosted by CoVentured. While we have a relationship with CoVentured, we do not endorse or guarantee any CoVentured website and we disclaim any liability relating thereto. The CoVentured website will also have different security and privacy policies and practices. By continuing, you acknowledge and agree to the foregoing.
We are looking for wild card applicants with novel products, technology, services or ideas to help drive growth for our key brands in our three regions – Australia & New Zealand, South Africa and Asia.
Our key focus categories for this wild card challenge include:
skincare – specifically, sun care, baby skin care, and skin conditions like: extreme sensitive skin, extreme dry skin, psoriasis, eczema, rosacea, keratosis pilaris, acne
throat, cough, cold, flu, sinus, allergy – including all stages of the cycle from: prevention > early signs > peak sickness > recovery > prevention > immune boosting
feminine health – specifically covering stages of a female life from: puberty > pre-conception > pregnancy > post partum > pre-menopause > post-menopause
The following describes our ideal solution, but not all criteria needs to be met to apply.
your idea, technology, or solution addresses a health need and consumer benefit in one of these focus categories
your solution is a strong fit for our key brands and complement to its range
your solution can be implemented in at least one of our three regions – ANZ, RSA and Asia
you are willing and authorised to negotiate an agreement to potentially partner with iNova Pharmaceuticals to implement the solution
you/your organisation is nimble and able to support fast implementation of your solution
What is the Opportunity?
The leading Innovator will choose how they want to work with iNova Pharmaceuticals to implement the solution.
What is the Process?
Shortlisted applicants will be asked to sign a Mutual Confidentiality Agreement with iNova before proceeding to our due diligence phase. The chosen finalists will then pitch their solution and partnership proposal to the iNova executive team. The leading solution(s) will then be launched into one or more of our regions, under the mutually agreed partnership model.
Who Should Apply?
If you or your organisation has an idea, technology or solution which can help deliver growth for our key brands in the nominated “Wild Card” categories, then please APPLICATIONS NOW CLOSED.
Products featured in this website or on the photos/images may or may not be approved or available in the country that you are accessing this website from. iNova’s products will have different labelling and be subject to different regulatory requirements in different countries. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product that is not approved under the laws and regulations of the country that you are accessing this website from.
NOTICE: You are leaving the iNova Pharmaceuticals website and are being directed to a website hosted by CoVentured. While we have a relationship with CoVentured, we do not endorse or guarantee any CoVentured website and we disclaim any liability relating thereto. The CoVentured website will also have different security and privacy policies and practices. By continuing, you acknowledge and agree to the foregoing.
With over 500 staff members globally, iNova has offices located in seven countries.
Our group Head Office is located in Singapore.
We also have regional/country offices in:
Australia – Chatswood, Sydney
South Africa – Bedfordview, Johannesburg
Asia – Thailand, Malaysia, Philippines, Singapore & Hong Kong
BLIS PROBIOTICS was an established local brand in New Zealand when it joined the iNova portfolio in 2018, through a long-term exclusive license and distribution arrangement with BLIS Technologies.
BLIS PROBIOTICS is the world’s first market-approved targeted throat probiotic, discovered by Australian Professor, John Tagg, and further developed and commercialised by BLIS Technologies in New Zealand. BLIS Technologies shares iNova’s core values of innovation, expertise and desire to improve the health and wellbeing of our customers. The ongoing partnership between iNova Pharmaceuticals and BLIS Technologies leverages the strengths and expertise of both parties.
The BLIS PROBIOTICS Australian launch in 2019 – dubbed the most exciting product launch in the probiotic category for the year – was fast tracked by a full year and was executed within 6 months.
Supported by a dedicated iNova team, the launch incorporated a comprehensive marketing program including Australian packaging design, in-store promotion, television commercial, display advertisements, targeted online videos, advertorials and influencer partnerships to drive consumer awareness and trial during the launch period. To build professional awareness and recommendation, iNova also rolled out an education program targeting Pharmacists and Pharmacy Assistants nationally.
With a unique value proposition, success and loyalty in its home market and potential for geographic expansion, BLIS PROBIOTICS is exactly the kind of brand we look to own or distribute at iNova Pharmaceuticals.
Our door is always open to prospective vendors and business partners here at iNova Pharmaceuticals!
Founded in South Africa in 2007, the Creche Guard product range was acquired by iNova Pharmaceuticals from Kenza Health in January 2018.
Under the ownership of iNova Pharmaceuticals, Creche Guard has firmly established itself as South Africa’s #1 Children’s Multivitamin.
iNova’s wide market reach and distribution, and increased investment in advertising and promotion, has seen the product grow at double digit rates during the first 18 months of ownership.
The iNova South Africa team has delivered a suite of engaging consumer campaigns, including an engaging Garder Facebook campaign, a vibrant Dis-Chem Back-To-School Promo and playfully colourful AlphaPharm display drive.
Creche Guard is exactly the kind of brand we look to own or distribute at iNova Pharmaceuticals – a high-quality and efficacious Consumer Health product, with a small but established reputation amongst consumers and healthcare professionals, in markets that we are familiar with, with great branding and the potential to grow.
Our door is always open to prospective vendors and business partners here at iNova Pharmaceuticals!
Quality &
Integrity
We know that families trust us with their health and well-being, and we treat that obligation very seriously. We all have our own families, so we are totally committed to delivering products that meet top quality standards that are promoted in an accurate and balanced manner.
We have a large Operations team globally who oversee the manufacture and supply of our products into the hands of end users. We have very high expectations of our manufacturers and we test our products rigorously.
We are also committed to acting with integrity and maintaining the highest ethical standards.
Growth
Since late 2017, our business has been on a new trajectory. We have plans for accelerated growth and we have the investment firepower to execute those plans. It is an exciting period to be a part of iNova!
We are actively developing an organic pipeline of products through a fully resourced Innovation team.
We are also actively seeking to grow through business development activity.
We are looking for people that want to be a part of our growth story.
Health &
Well-being
True to our mission, we care deeply about health and well-being at work.
We offer a number of staff benefits and programs aimed at supporting and improving the health and well-being of our staff. For example, in Australia we have weekly Yoga classes in Head Office, we offer an Employee Assistance Program (EAP), and all staff receive health snacks (or healthy snack allowances for field-based staff). In South Africa, we offer the Unmind program.
Privacy Collection Statement
iNova may share your reported adverse event with third parties that we engage to process adverse events and enquiries on our behalf. iNova may also use the information to maintain records of reports and to investigate or follow up on your report. If you are providing us with someone else’s personal information, you confirm that you have obtained their consent to do so. iNova will share the details of your reported side effect with the various Partners, Health and Regulatory Authorities in your country and in countries around the world as mandated by law; no personally identifiable details in that instance will be shared.
If iNova receives information regarding a side effect with another company’s product, we are mandated by Health Authority regulations to share that information with that company. You may be contacted by that company for additional information regarding the side effect with their product.
You can view further details on how we manage personal information in our privacy policy at https://inovapharma.com/privacy. If you have any questions or concerns regarding the management of your personal information, please contact privacy@inovapharma.com.
Innovation
Innovation is a big part of our strategic plan.
We have invested heavily in product sourcing and development, and we have a rich pipeline of new products due to launch in all of our regional markets during the next few years.
We also support and incentivise innovation in all other areas of our business.
Reward &
Recognition
We have a well-established Reward and Recognition programs that rewards staff in all of our markets.
We have our annual CEO Awards, recognising our highest achievers across the group in Sales, Non-Sales, Values and Innovation.
We also have an annual gala awards function, where both Sales and Non-Sales staff are recognised for outstanding achievement.
We also have Values and Service awards that are handed out locally throughout each year.
Diversity &
Inclusion
We aim to provide a work environment where people are treated fairly and with respect.
We recognise that the work environment should be free from unlawful or unwelcome conduct.
We affirm the right of every person to equal employment opportunities.
Learning &
Development
Whatever your role, we are committed to help you to develop your expertise within that role and, if you are interested, to prepare you for opportunities beyond your current role.
Staff at iNova have plenty of opportunities to get involved in cross-functional and innovation projects at a local and global level!
We also offer our employees the opportunity to participate in a range of more structured external and internal learning and development opportunities.
In South Africa, we have the Career Advancement Plan (CAP) for the sales force and iLead program.
In Asia, we offer company-sponsored external training activities, including study leave.
In Australia, we have a Learning & Development Program for all staff, with blended learning experience of face to face, online & self-directed learning.
Giving back
We are very committed to giving back to our local communities. We do that in a variety of different ways in each region.
Each region has a formal community/charitable giving program which involves workplace giving as well as initiatives that allow you to get directly involved in the work of our community/charity partners. In Australia, iNova matches staff donations.
At a global level, we additionally support a number of important causes from time to time.
Heritage
We are very proud of our history.
We have a very diverse portfolio of products, many of which have been used in family medicine cabinets all over the world for many decades.
You can read more about our the story of our products and the history of iNova here.
Staff benefits
We know people perform at their best when they feel looked after at work!
Our staff benefits vary from region to region, so please see your regional Careers page for more information about local benefits.
Some of our staff benefits include:
[Competitive remuneration and a generous incentive scheme]
Paid parental leave
Additional annual leave days each year
Professional learning and development support
Salary continuance and Personal Accident insurance
Flexible working opportunities
Opportunities to get involved in charitable initiatives
Staff shop (opportunity to purchase iNova products at significantly discounted prices)
Reward and Recognition Program
Employee Assistance Program (EAP)
Employee Referral Bonus
Financial Wellness education
Healthy snacks (or healthy snack allowance for remote staff)
Our
Culture &
Values
Our Values are the foundation of our global culture. They determine (and reflect) how we work every day.
We are always on the lookout for passionate, proactive and positive people to join our business.
We are looking for innovators, contributors, owners, entrepreneurs… people that can move fast and make things happen. Our people are empowered to act and make decisions locally.
We want people who put our patients and our customers at the centre of everything they do, and that are committed to excellence in their role.
We are looking for people who can collaborate with internal and external stakeholders, often across different functions and markets, to achieve shared success.
We want people who have integrity and that understand the regulatory environment that we work in.
Read more about our Vision and Values over here.
NOTICE: You are leaving our website. iNova does not have any links with these third parties. Any information provided by this source should be discussed with your healthcare professional and does not replace their advice. We are providing links to third-party websites solely as a convenience to you, because we believe that these websites may provide useful content. We are not, by referring or linking to the third party website, incorporating its contents into our own website. We do not endorse or guarantee and (to the maximum extent permitted by law) we disclaim any responsibility for: the content, products or services offered on these websites, their performance or interaction with your computer, their security and privacy policies and practices, and any consequences that may result from visiting these websites. These third-party sites may have their own privacy policies. You should review the privacy policy of any website before you provide personal or confidential information. By clicking to continue, you acknowledge and agree to everything we say above. You are now leaving our website.
